Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Russano M, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G. Cortellini A, et al. Among authors: guida a. Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12. Eur J Cancer. 2021. PMID: 33721704 Free article.
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G. Iacovelli R, et al. Among authors: guida a. Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29. Urol Oncol. 2017. PMID: 28572027
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, Pignata S, Palumbo R, Ceresoli GL, Del Conte G, Tonini G, Morelli F, Nolè F, Panni S, Rondini E, Guida A, Zucali PA, Doni L, Iezzi E, Caminiti C. Passalacqua R, et al. Among authors: guida a. BMC Cancer. 2017 Jul 19;17(1):493. doi: 10.1186/s12885-017-3466-3. BMC Cancer. 2017. PMID: 28724419 Free PMC article.
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. Iacovelli R, et al. Among authors: guida a. Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. Anticancer Drugs. 2018. PMID: 29846246
Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.
Masini C, Vitale MG, Maruzzo M, Procopio G, de Giorgi U, Buti S, Rossetti S, Iacovelli R, Atzori F, Cosmai L, Vignani F, Prati G, Scagliarini S, Guida A, Berselli A, Pinto C. Masini C, et al. Among authors: guida a. Clin Genitourin Cancer. 2019 Feb;17(1):e150-e155. doi: 10.1016/j.clgc.2018.10.001. Epub 2018 Oct 10. Clin Genitourin Cancer. 2019. PMID: 30396828
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Cortellini A, et al. Among authors: guida a. J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421. J Immunother Cancer. 2021. PMID: 33827906 Free PMC article.
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.
Metro G, Baglivo S, Bellezza G, Mandarano M, Gili A, Marchetti G, Toraldo M, Molica C, Reda MS, Tofanetti FR, Siggillino A, Prosperi E, Giglietti A, Di Girolamo B, Garaffa M, Marasciulo F, Minotti V, Gunnellini M, Guida A, Sassi M, Sidoni A, Roila F, Ludovini V. Metro G, et al. Among authors: guida a. Genes (Basel). 2021 Apr 30;12(5):679. doi: 10.3390/genes12050679. Genes (Basel). 2021. PMID: 33946594 Free PMC article.
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study.
Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García-Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom-Davis T, Gennari A, Cortellini A; OnCovid study group. Pinato DJ, et al. Lancet Oncol. 2021 Dec;22(12):1669-1680. doi: 10.1016/S1470-2045(21)00573-8. Epub 2021 Nov 3. Lancet Oncol. 2021. PMID: 34741822 Free PMC article. Clinical Trial.
347 results